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Introduction: A massive increase of soluble thrombomodulin (sTM) due to variants in
the thrombomodulin gene (THBD) has recently been identified as a novel bleeding dis-
order.
Aim: To investigate sTM levels and underlying genetic variants as a cause for haemo-
static impairment and bleeding in a large number of patients with a mild to moderate
bleeding disorder (MBD), including patients with bleeding of unknown cause (BUC).
Patients and methods: In 507 MBD patients, sTM levels, thrombin generation and
plasma clot formation were measured and compared to 90 age- and sex-matched
healthy controls. In patients, genetic analysis of the THBD genewas performed.
Results: No difference in sTM levels between patients and controls was found overall
(median ([IQR] 5.0 [3.8-6.3] vs. 5.1 [3.7-6.4] ng/ml, p = .762), and according to specific
diagnoses of MBD or BUC, and high sTM levels (≥95th percentile of healthy controls)
were not overrepresented in patients. Soluble TM levels had no impact on bleeding
severity or global tests of haemostasis, including thrombin generation or plasma clot
formation. In the THBD gene, no known pathogenic or novel disease-causing variants
affecting sTM plasma levels were identified in our patient cohort.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and is not used for commercial purposes.
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Conclusion: TM-associated coagulopathy appears to be rare, as it was not identified
in our large cohort of patients with MBD. Soluble TM did not arise as a risk factor for
bleeding or altered haemostasis in these patients.
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1 INTRODUCTION
Patients with mild to moderate bleeding tendency (mild bleeding dis-
orders, MBD) suffer from a life-long history of diverse bleeding symp-
toms such as epistaxis, easy bruising, menorrhagia or bleeding after
tooth extractions.1–3 Severe spontaneous bleedings are rare, which
is why patients are often not diagnosed until adulthood.3 Still, under
certain haemostatic challenges, such as surgery or childbirth, bleed-
ing can be even life-threatening. A vast majority of patients with MBD
remains without a definite diagnosis, despite thorough haemostatic
investigations of plasmatic coagulation and platelet function.1 Patients
with bleeding of unknown cause (BUC) do not differ phenotypically
from patients with an established diagnosis,1,4 and were found to have
impaired thrombin generation and plasma clot formation.5 This under-
lines the urgent need to identify underlying mechanisms of bleed-
ing in BUC patients,6 leading to better diagnostic and therapeutic
approaches.7
Recently, several groups described a thrombomodulin (TM) -
associated coagulopathy with a 100-fold enhancement of soluble TM
(sTM).8–11 The routinely performed coagulation tests, like the acti-
vated partial thromboplastin time (aPTT) or prothrombin time (PT),
platelet function, and clotting factor levels were all within the normal
range, whereas thrombin generation was impaired.8
Thrombomodulin is a transmembrane glycoprotein primarily
located on endothelial cells of capillary vessels, which is not only
involved in coagulation but also in immune processes, inflammation
and cell-proliferation.12 By forming a complex with thrombin, TM
becomes an essential co-factor for both the natural anticoagulant
protein C and also for the thrombin-mediated activation of the throm-
bin activatable fibrinolysis inhibitor (TAFI).12,13 Activated protein
C (APC) with its co-factor protein S is a key enzyme for the natural
anticoagulation of activated coagulation factors (F) V and VIII.14 On
the other hand, thrombin-TM complexes also have been shown to
delay fibrinolysis by activation of TAFI, independently of APC.12,15,16
The encoding gene for TM is THBD, which consists of only one exon
on chromosome 20. For the TM-associated coagulopathy, two vari-
ants in the THBD gene have been identified in different families that
code for a premature stop codon: c.1611C > A; p.Cys537Stop and
c.1487delCM; p.Pro496Argfs*10. These nonsense variants lead to a
loss of theC-terminal portionof the transmembranehelix and the cyto-
plasmatic domain of TM.8 The resulting introduction of a negatively
chargedC-terminusof TMand the loss of interactionwith the cytoplas-
matic domain result in the shedding of TM from the endothelium into
the plasma.9,17 The high sTM levels induce persistent APC activation,
which then further inactivates FVa and FVIIIa.9
Few genetic variants in the coding region of THBD
are observed within the population database (gno-
mAD_v3). The most prevalent being a non-synonymous vari-
ant rs1042579, NM_000361.3:c.1418C>T p.Ala473Val (GRCh38.p12
chr 20:23048087G>A).
Based on the recent findings in patients with TM-associated coag-
ulopathy, we systematically investigated levels of sTM in a well-
characterized cohort of patients with MBD, including a large number
of BUC patients. Furthermore, we assessed how increased sTM lev-
els affected global coagulation tests, particularly the thrombin genera-
tion assay and plasma clot formation, aswell as the bleeding phenotype
in our patients with MBD. To identify known or novel genetic variants
within the THBD gene inMBD, genetic data were analysed.
2 METHODS
2.1 Study design and patients
Recruitment of patients with MBD in the Vienna Bleeding Biobank
(VIBB), a prospective single-centre cohort study, started in October
2009 and is on-going. Patients aged ≥ 16 years without a previously
diagnosed bleeding disorder were included. Detailed inclusion- and
exclusion criteria were published recently1 and are summarized in
Supplementary table 1. The bleeding phenotype and severity were
assessed by two standardized scores, the Vicenza bleeding score (BS)
and the ISTH BAT. In the current analysis, 507 patients who were
included in the study until March 2017were investigated.
Ninety age-and sex-matched healthy controls were recruited by
trained healthcare personnel for comparison.
The study has approval by the Ethics Committee of the Medical
University Vienna (EC No 603/2009) according to the Declaration of
Helsinki of 1975.
2.2 Blood sampling, laboratory analyses
After study inclusion, samples were timely processed to routine
laboratory assessments and to storage at the biobank facility of
the Medical University of Vienna (www.biobank.at, Supplementary
paragraph 1).18 Routinely performed analyses included the assess-
ment of plasmatic coagulation and platelet function (Supplementary
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table 2). Assessment of thrombin generation and plasma clot formation
is described in Supplementary paragraph 2 and 3.
2.3 Established diagnoses
The diagnostic criteria applied in the study to classify patients are
reported in Supplementary table 3. Due to the low number of only
2 patients, patients with dys-/hypofibrinogenemia were not analysed
separately in this study.
2.4 Determination of sTM levels
The determination of sTM was performed using a commercially avail-
able ELISA (ab46508 – Thrombomodulin (CD141) Human ELISA Kit
– Abcam, Cambridge, United Kingdom) from samples stored at the
biobank.
2.5 Statistical and bioinformatic analysis
Statistical analysis was performed with the Statistical Package for
Social Sciences (SPSS IBMVersion 26.0) and the free open-source soft-
ware GNUR version 3.5.3.19
Variables aredescribedbymean (and standarddeviation), ormedian
(and interquartile range), in case of non-normal distribution. Group
comparison was performed using the Student’s t-test or theWilcoxon-
rank-sum-test in caseof non-normal distribution for unadjustedgroups
and the chi-square or Fisher’s exact test were used for comparing cate-
gorical variables.Comparisonsbetweendiagnoses aswell as genotypes
and sTM levels were performed using a Kruskal-Wallis test.
To evaluate the adjusted differences for sTM levels between
patients and healthy controls multiple linear regression analysis (con-
sidering sex and age as confounding variables) was applied. The odds
ratio (confidence interval 95%) for having sTM values above the pre-
defined cut-off were calculated with logistic regression (considering
sex, age and blood group O as confounding variables).
To account for the number of multiple comparisons performed
within the individual secondary research questions, the Bonferroni-
Holm correction was accordingly applied. All p-values are results of
two-sided tests, and p-values< .05were considered as statistically sig-
nificant.
Genetic data come fromgenetic high-throughput sequencingwithin
the ThromboGenomics platform.20 Bioinformatic analysis is described
in detail in Supplementary paragraph 4.
3 RESULTS
3.1 Patients’ characteristics
Five hundred and seven patients with MBD were included in this
study, of whom 358 (70.6%) had BUC. Eighty-four patients (16.5%)
had a possible or definite platelet function defect (PFD), and VWD
TABLE 1 Demographic and laboratory data of all patients with
MBD and healthy controls
All patients with
MBD (n= 507) Controls (n= 90)
Female, n (%) 412 (81.3) 73 (81.1)




Caucasian, n (%) 505 (99.6) 89 (98.9)
mean (SD) mean (SD)
Age, years 41.6 (15.8) 42.6 (15.2)
BMI, kg/m2 24.2 (4.5) 23.9 (7.1)
Haemoglobin, g/dL 13.6 (1.3) 14.4 (4.2)
Platelet count, x109/L 250.9 (66.6) 260.9 (48.6)
Fibrinogen, mg/dL 316.6 (72.6) 292.8 (63.1)
median (IQR) median (IQR)
aPTT-STA, seconds 35.8 (33.6-38.7) 34.7 (32.9-36.1)
Prothrombin time, % 95.0 (88.0-102.0) 101.0 (91.5-109.0)
FVIII, % 121.0 (96.0-155.0) 135.5 (106.3-158.8)
FIX, % 105.0 (90.0-121.0) 102.5 (89.0-117.0)
VWF:Ag, IU/dL 95.0 (74.0-121.0) 104.0 (89.25-134.0)
VWF:RCo, IU/dL 79.0 (63.3-122.0) 100.0 (77.0-137.0)
mean [SD] mean [SD]
Vicenza bleeding score 5.7 (3.0) 0 (0)
ISTH BAT2 6.5 (3.5) na
1Blood group available of 73 healthy controls.
2ISTH bleeding score available of 250 patients (49.3%).
Abbreviations: na, not available; BMI, bodymass index; aPTT-STA, activated
partial thromboplastin time, according to the STA coagulation analyzer;
FVIII, factor VIII activity; FIX, factor IX activity, VWF: Ag, Von Willebrand
Antigen; VWF:RCo, VonWillebrand factor ristocetin cofactor activity.
(VWF≤30 IU/dL) or low von-Willebrand factor (VWF31–50 IU/dL)was
diagnosed in 43 patients (8.5%). Further diagnoses were coagulation
factor deficiencies (CFD, n = 21, 4.1%), and hypo-/dysfibrinogenemia
(n= 2, .4%).
Patients’ characteristics and laboratory results are summarized in
Table 1. Blood group O was overrepresented in the patient cohort.
Patients had a prolonged aPTT and PT and lower levels of von VWF
antigen (VWF:Ag) and activity (VWF:RCo) than healthy controls, albeit
the values were within the normal range.
3.2 Levels of soluble thrombomodulin
Soluble TM was not altered in patients when comparing to 90 sex-
and age-matched healthy controls (median [IQR] 5.0 [3.8-6.3] vs. 5.1
[3.7-6.4] ng/ml, p = .762). In the patient group, men had higher sTM
levels thanwomen (5.8 [4.4-7.2] vs. 4.8 [3.7-6.1] ng/ml, p< .001), which
could not be seen in healthy controls (men: 5.9 [4.8-6.3] vs. women:
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n (%) median [IQR] p p1 n (%) OR1 [95%CI]
Healthy controls 90 (100) 5.1 [3.7-6.4] na na 4 (5.54) na
All patients withMBD 507 (100) 5.0 [3.8-6.3] .762 .306 10 (2.0) 1.8 [.5-6.9]
BUC 358 (70.6) 5.0 [3.8-6.3] .789 .661 6 (1.7) 2.4 [.6-10.0]
PFD2 84 (16.6) 5.1 [3.7-7.1] .759 .724 4 (4.4) .8 [.1-4.4]
VWF≤50 IU/dL1 43 (8.5) 4.5 [3.2-5.9] .202 .482 0 (0) na
CFD 21 (4.1) 4.9 [4.4-6.0] .913 .900 1 (4.8) .6 [.4-9.2]
Abbreviations: MBD, mild bleeding disorder; sTM, soluble thrombomodulin; OR, odds ratio; IQR, interquartile range; BUC, bleeding of unknown cause; PFD,
platelet function defect; VWF, vonWillebrand factor; CFD, coagulation factor deficiency.
1adjusted for sex, age and blood groupO inmultivariate analysis.
2one patient had both a PFD and VWF≤50 IU/dL, two patients also hadmild FXI deficiency.
F IGURE 1 Scatter plot (includingmean and SD) of soluble TM
levels in patients and healthy controls. Abbreviations: sTM, soluble
thrombomodulin; BUC, bleeding of unknown cause; PFD, platelet
function defects; VWF, vonWillebrand factor≤ 50 IU/dL; CFD,
clotting factor deficiency
5.0 [3.5-6.4] ng/ml, p= .116). No strong correlations with age (r= .133,
p= .003) or BMI (r= .077, p= .085) were identified in patients.
In multivariate analysis when adjusting for sex and age, there was
no significant difference in sTM levels between patients and healthy
controls (Table 2).When analysing sTMvalues according to established
diagnoses of bleeding disorders or BUC, no differences in sTM levels
were found in one of the subgroups in comparison to healthy controls
(Figure 1, Table 2). There was no overall difference between subgroups
of diagnoses either (Kruskal-Wallis, p= .091).
To identify outliers of sTM levels in our patients, a cut-off according
to the 95th percentile of sTM levels in healthy controls (≥ 14.7 ng/ml)
was defined. No increased number of patients above the predefined
cut-off was identified (Table 2). In line, also in separate analysis of
patients with established diagnoses or BUC, no increased number of
patients with very high sTM levels above the cut-off was found.
3.3 Correlation of sTM with the bleeding
phenotype
When analysing the influence of sTM on the bleeding phenotype, no
clear correlation was found with the number of bleeding manifesta-
tions (r = -.088, p = .048), the Vicenza BS (r = -.055, p = .214) or the
ISTH BAT (r = -.067, p = .292). No moderate or strong correlations
between the bleeding scores and sTM levels were observed in the sep-
arate analysis of each diagnosis and BUC, also after adjustment for sex
(Table 3). Mild positive correlations between sTM levels and the num-
ber of bleeding symptoms and the Vicenza BS were found in patients
with VWF≤50 IU/ml after adjustment for sex in linear regression anal-
ysis (Table 3).
When comparing the bleeding phenotype between patients with
sTM levels < 95th percentile of healthy controls and those with val-
ues≥95th percentile, therewas no significant difference in the number
of bleeding manifestations or bleeding severity (Supplementary table
4). Patients with BUC and very high sTM values ≥ 14.7 ng/ml had a
slightly higher number of bleeding manifestations and ISTH BAT val-
ues, but lacking significant difference. There was no difference in the
prevalence of specific bleeding symptoms between patients with sTM
values above or below 14.7 ng/ml (Supplementary table 5).
3.4 Correlation of sTM levels with global
coagulation tests, thrombin generation and fibrin clot
formation
No moderate or strong correlations were identified between sTM val-
ues and aPTT, PT, parameters of thrombin generation or plasma clot
formation (Table 4). The PT showed a weak inverse correlation with
sTM levels in PFD patients only.
There were no differences in global coagulation tests, parameters
of thrombin generation and plasma clot formation between patients
with high sTM levels above and below the 95th percentile of healthy
controls (Table 5). Also, in the separate analysis of each diagnosis and
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r β r β r β
All patients withMBD −.088* .023 .002 .010 −.067 −.012
BUC −.126* .006 −.084 −.020 −.059 .006
PFD −.073 −.103 .018 −.008 −.054 −.049
VWF≤50 IU/dL .097 .311* .125 .313* −.129 −.061
CFD .254 −.159 .030 −.285 .110 −.703
Abbreviations: BS, bleeding score; BAT, bleeding assessment tool; BUC, bleeding of unknown cause; PFD, platelet function defect; VWF, von Willebrand
factor; CFD, coagulation factor deficiency.
r, correlation coefficient (Spearman-rho).
β, regression coefficient (linear regression with adjustment for age, sex and blood groupO).
Weak (.2-.4), moderate (.4-.6), strong (.6-.8) and very strong (.8-1.0) correlations.
Significance: *p< .05; **p< .01; ***p< .001; ns: not significant.
TABLE 4 Correlation of sTMwith global coagulation tests and parameters of thrombin generation and plasma clot formation in all patients
withMBD and according to diagnoses
Controls
All patients with
MBD BUC PFD CFD
n= 90 n= 507 n= 358 n= 84 n= 21
aPTT, seconds −.168 ns −.015 ns −.008 ns −.027 ns .286 ns
PT, % .109 ns −.096* −.074 ns -.329 *** .029 ns
Thrombin generation assay n= 46 n= 507 n= 358 n= 84 n= 21
Lag time, min −.180 ns .097* .106 * .072 ns .412 ns
Velocity index, nmol/L/min .222 ns −.038 ns −.083 ns .103 ns −.133 ns
Peak thrombin, nmol/L .211 ns −.048 ns −.093 ns .070 ns −.052 ns
TTP, min −.169 ns .056 ns .081 ns −.028 ns .285 ns
AUC, nmol/L xmin .082 ns −.079 ns −.107 * −.038 ns −.009 ns
Plasma clot assay n= 46 n= 507 n= 358 n= 84 n= 21
Lag time, min −.150 .062 ns .110 * −.110 ns .178 ns
ΔAbs, OD 405 nm .168 ns .002 ns −.032 ns .146 ns .196 ns
TTP, min −.049 .045 ns .070 ns −.036 ns .213 ns
Vmax, OD/min .263 ns −.057 ns −.110 * .048 ns −.021 ns
CLT, min .365* −.040 ns −.053 ns .023 ns −.390 ns
sTM, soluble thrombomodulin; BUC, bleeding of unknown cause; PFD, platelet function defects; aPTT, activated partial thromboplastin time; PT, prothrombin
time; AUC, area under the curve; CLT, clot lysis time; OD, optical density; TTP, time to peak.
Weak (r= .2-.4), moderate (r= .4-.6), strong (r= .6-.8) and very strong (r= .8-1.0) correlations (Spearman).
Significance: *p< .05; **p< .01; ***p< .001; ns: not significant.
BUC there was no difference in global coagulation tests, parameters of
thrombin generation and plasma clot formation between patients with
high sTM levels above and below the 95th percentile of healthy con-
trols (data not shown).
3.5 Genetic analysis
Sequencing and genotyping data were available in 503 of the 507
patients (99%). The known variations c.1611C > A; p.Cys537Stop and
c.1487delCM; p.Pro496Argfs*10, causal for a TM-associated coagu-
lopathy, were not identified in our patients. The most common variant
was found in rs1042579 with 18 homozygous individuals (3.5%), and
151 heterozygous patients (30%). There was no impact of this variant
on sTM levels in individuals being homozygous, heterozygous or not
carrying the variation rs1042579 (Supplementary figure 1). Coverage
analysis did not show any evidence of copy number variations for the
THBD gene region in patients with above-average sTM levels. In addi-
tion, nine other variants were found in 23 individuals (Supplementary
table 6). All of them were present as heterozygous variants, none of
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(≥ 14.7 ng/ml) p BHC
aPTT, seconds, median (IQR) 35.8 (33.6-38.7) 38.1 (35.6-45.4) .056 ns
PT, %, mean (SD) 95.2 (11.4) 89.3 (12.0) .106 ns
Thrombin generation assay1
Lag time, min, mean (SD) 11.3 (3.1) 10.9 (2.3) .656 ns
Velocity index, nmol/l/min, median (IQR) 29.7 (15.4-50.1) 25.1 (13.1-32.3) .194 ns
Peak thrombin, nmol/L, mean (SD) 236.1 (119.8) 190.2 (95.7) .282 ns
TTP, min, median (IQR) 18.6 (15.6-22.1) 19.6 (17.9-21.4) .525 ns
AUC, nmol/l x min, mean (SD) 3167.2 (754.8) 3021.8 (1452.4) .786 ns
Plasma clot formation assay2
Lag time, min, median (IQR) 10.6 (7.7-14.3) 9.6 (6.5-22.3) .892 ns
ΔAbs, OD 405 nm, mean (SD) .72 (.18) .63 (.16) .114 ns
TTP, min, median (IQR) 19.5 (14.5-23.9) 16.1 (12.1-34.0) .646 ns
Vmax, OD/min, mean (SD) .13 (.10) .11 (.09) .186 ns
CLT, min, median (IQR) 15.6 (13.1-18.9) 13.9 (12.2-21.0) .715 ns
Abbreviations: IQR, interquartile range; BHC, Bonferroni-Holm correction; TTP, time to peak; AUC, area under the curve; CLT, clot lysis time; OD, optical
density
1data of thrombin generation assay available of 493 (99.2%) patients sTM< 95th percentile and 8 (80.0%) patients with sTM≥ 95th percentile.
2data of plasma clot assay available of 497 (100%) patients with sTM< 95th percentile and 10 (100%) patients with sTM≥ 95th percentile.
them were predicted by VEP to have a high impact and no significant
correlation with sTM levels was found.
4 DISCUSSION
In this study, we did not identify increased levels of sTM in plasma of
patients with MBD compared to healthy subjects, also when analysing
patients with BUC or established diagnoses of MBD separately. Solu-
ble TM levels were not associatedwith the bleeding phenotype. Global
coagulation tests, and parameters of thrombin generation and plasma
clot formation were not affected by increased sTM values. In bioinfor-
matic analysis of the TM encoding gene (THBD), we did not identify
variants that influenced sTM levels.
Thrombomodulin is a transmembrane protein expressed on
endothelial cells of all vessels, which besides its traditional role in
coagulation and fibrinolysis, possesses several other functions.12
Depending on the structural region of TM, it interferes with the com-
plement system and leukocyte trafficking, therefore playing a major
role in inflammation. Under physiological conditions, very low levels of
sTM inplasmaare detectable.21 During inflammation, immune cells are
also able to induce cleavage of endothelial TM resulting in the shedding
of TM into circulating blood. Enhanced levels of sTM can therefore
be seen as a biomarker for endothelial damage. The exact shedding
mechanism is not fully understood, and translational data suggest that
proteinases belonging to the matrix metalloproteinases family to be
involved in the shedding process.22 Interestingly, Jourdy et al. did not
find high shear stress to play a role in the shedding of TM.21 Also, an
increase of sTM has been reported in disease like rheumatoid arthritis,
systemic lupus erythematosus and systemic sclerosis, where sTM was
found to be associatedwith disease activity.23,24 Patients in our cohort
are selected according to precise exclusion criteria covering also acute
inflammatory processes.1
In affected patients with TM- associated coagulopathy, levels of
sTM are up to 100-fold higher than the normal reference of around
3–8 ng/ml.9,11,25 In our cohort, no suchmassively increased sTM levels
were found. Nevertheless, also a slight increase in sTM was identified
as a risk factor for clinical relevant and major bleeding in patients on
oral anticoagulants.26,27 These findings emphasize the possible role of
sTM as a clinically relevant marker of increased bleeding risk. In our
cohort of patients with MBD and BUC, no associations of sTM values
with bleeding severity and the bleeding phenotype were identified.
Our recent findings and those of others suggest, that bleeding scores
have a low sensitivity for diagnosing a bleeding disorder and that most
mild to moderate bleeding symptoms are not predictive for diagnosing
aMBD.3,4 The lackof correlations of sTMwith thebleeding scoremight
also base on amultifactorial aggregation of distinct risk factors that are
only partially responsible for the bleeding outcome in BUC patients,
as reviewed by Mezzano et al.7 For example, we recently identified
blood group O as a risk factor for increased bleeding severity.6 This
hypothesis of a multifactorial aggregation of risk factors underlying
the bleeding tendency in patients withMBDwas also addressed in our
analysis by including patients with a definite diagnosis of a bleeding
disorder. In these patients with a known haemostatic defect, the
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individual bleeding phenotype often is independent of residual coag-
ulation factor levels.4,28 Amongst other factors, also natural antico-
agulants have been shown to impact the individual bleeding tendency
in patients with an established bleeding disorder.29 Nevertheless, in
this analysis we could not observe an impact of sTM on the bleeding
severity in patients irrespective of the diagnosis of a bleeding disorder.
We found higher sTM values in men than in women in our patients,
which is in agreement with earlier studies in healthy controls,25 never-
theless, our healthy subjects did not reach a significant significance.
In line with reported results in patients with a TM- associated coag-
ulopathy, we did not see a strong correlation between sTM levels and
PT or aPTT.9,11 Interestingly, there was a weak negative correlation
between sTM levels and the PT, suggesting an impaired haemostatic
potential which only occurred in patients with PFD. Due to the versa-
tile and probably also unknown properties of sTM, we do not have an
obvious explanation for this association, which could also be by chance
from a statistical point of view. In detail, the anticoagulant function of
sTM bases on protein C activation, which then, together with its cofac-
tor PS, cleaves FVaandFVIIIa and thus inhibits coagulation.12,30 There-
fore, the PT is not sensitive for this intrinsic mechanism. Additionally,
the aPTT assay is usually not affected by high sTM levels either, as
in this assay thrombin is formed very rapidly so that the anticoagula-
tion properties of sTM cannot come into effect.9 On the other hand,
a reduced thrombin generation was observed in patients with a TM-
associated coagulopathy.9 In our cohort, we did not find an effect of
sTM levels on thrombin generation or plasma clot formation in the
overall cohort. This suggests that sTM must reach a very high thresh-
old to affect thrombin generation and thus the haemostatic balance.
THBD is a small gene consisting of one exon, and most described
variations in this gene were associated with thrombotic events and
atypical haemolytic-uremic syndrome.31–33 The two mutations in the
THBD gene underlying the TM- associated coagulopathy were only
found in single cases and families, which suggests a rare inheritance
trait. In our cohort, we could not identify thesemutations.
In total, 10 variations within the THBD gene were identified in our
cohort, but none of them had a significant impact on sTM levels. The
most common variant in our study was the rs1042579 (GRCh38.p12
chr 20: NC_000020.11:g.23048087G > A/T), which had the same
prevalence in our cohort as in the general population (gnomAD, Fis-
cher’s exact test for Hardy-Weinberg equilibrium p = .5271).34 This
variation results in an Alanine to Valine substitution (p.Ala473Val) and
is classified as benign based on the clinical significance as reported
dbSNP. This variant was also reported by Langdown et al in a heterozy-
gous form in one subject with TM-associated coagulopathy, whereas
it was not present in other family members who had a milder clinical
phenotype.9 On the other hand, homozygous genotypes of rs1042579
havebeenassociatedwith coronaryheart disease in somestudies,35–37
but data are inconclusive.38,39 In our study, this variant did not impact
levels of sTM.
Our study has some limitations: we were able to analyse the tar-
geted exonic region of the THBD gene, while the surrounding non-
coding areas not covered by sufficient sequencing reads could not
be analysed from our data on whole-exome sequencing of a high-
throughput sequencing panel of predefined genes within the Throm-
bogenomics project.20 In this previous study a molecular diagnostic
rate of only 3.2 % was achieved in BUC patients. This urges for more
comprehensive and broader genetic investigations to identify relevant
disease-causing variants in patients with MBD. Another limitation is
that in our cohort and control group the majority of patients were of
European ancestry, as this represents the population of our geographic
region andwas confirmed by genotyping.
According to our data, TM-associated coagulopathy is rare and
apparently of limited relevance in patients with a mild to moderate
bleeding tendency. Nevertheless, TM-associated coagulopathy should
be suspected especially in patients with severe undefined bleeding. In
a case of intra-abdominal bleeding during surgery in a patient, who
was later found to suffer from TM-associated coagulopathy, even a
broad therapeutic approach using desmopressin, tranexamic acid and
fresh frozen plasma could not stop the bleeding. Bleeding was finally
controlled by transfusion of platelets, which contain partially acti-
vated and intrinsically APC-resistant FV.8 Langdown et al reported
TM-associated coagulopathy in a family with massive bleeding follow-
ing physical trauma and surgery, as well as spontaneous intraabdomi-
nal bleedings in two affected family members.9 The patients reported
by Westbury et al suffered from a lifelong history of muscle and
joint bleeding after minor trauma.11 Published data underline, that
in patients with severe bleeding manifestations, including the above
mentioned symptoms, or an undefined severe bleeding tendency TM-
associated coagulopathy should be considered as a differential diagno-
sis.
In summary, we did not find an increase of sTM in patients with
MBD and there was no effect of sTM-levels on the bleeding pheno-
type. Furthermore, sTM levels did not affect thrombin generation or
plasma clot properties. We conclude that TM-associated coagulopa-
thy appears to be very rare and that the level of sTM within the range
that we observed in our patients with a bleeding tendency, was neither
associated with bleeding severity nor with any specific bleeding mani-
festation.
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